These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 19155198)

  • 1. Molecular biology of androgen-independent prostate cancer: the role of the androgen receptor pathway.
    Mellado B; Codony J; Ribal MJ; Visa L; Gascón P
    Clin Transl Oncol; 2009 Jan; 11(1):5-10. PubMed ID: 19155198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular biology of castration-resistant prostate cancer: basis for the novel therapeutic targets.
    Mellado B; Marin Aguilera M; Pereira MV
    Arch Esp Urol; 2013 Jun; 66(5):453-62. PubMed ID: 23793763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the androgen receptor pathway in prostate cancer.
    Chen Y; Sawyers CL; Scher HI
    Curr Opin Pharmacol; 2008 Aug; 8(4):440-8. PubMed ID: 18674639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in understanding hormonal therapy resistant prostate cancer.
    Donkena KV; Yuan H; Young CY
    Curr Cancer Drug Targets; 2010 Jun; 10(4):402-10. PubMed ID: 20464780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
    Vis AN; Schröder FH
    BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular alterations during progression of prostate cancer to androgen independence.
    Saraon P; Jarvi K; Diamandis EP
    Clin Chem; 2011 Oct; 57(10):1366-75. PubMed ID: 21956922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen receptor mutations for precision medicine in prostate cancer.
    Shiota M; Akamatsu S; Tsukahara S; Nagakawa S; Matsumoto T; Eto M
    Endocr Relat Cancer; 2022 Oct; 29(10):R143-R155. PubMed ID: 35900853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T-LAK cell-originated protein kinase (TOPK) enhances androgen receptor splice variant (ARv7) and drives androgen-independent growth in prostate cancer.
    Alhawas L; Amin KS; Salla B; Banerjee PP
    Carcinogenesis; 2021 Apr; 42(3):423-435. PubMed ID: 33185682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen action in the prostate gland.
    Yadav N; Heemers HV
    Minerva Urol Nefrol; 2012 Mar; 64(1):35-49. PubMed ID: 22402316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen receptor gene amplification: a novel molecular mechanism for endocrine therapy resistance in human prostate cancer.
    Koivisto P; Visakorpi T; Kallioniemi OP
    Scand J Clin Lab Invest Suppl; 1996; 226():57-63. PubMed ID: 8981668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unique targeting of androgen-dependent and -independent AR signaling in prostate cancer to overcome androgen resistance.
    Lim SC; Jansson PJ; Assinder SJ; Maleki S; Richardson DR; Kovacevic Z
    FASEB J; 2020 Sep; 34(9):11511-11528. PubMed ID: 32713076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of androgen receptor splice variants, their clinical relevance and treatment options.
    Wach S; Taubert H; Cronauer M
    World J Urol; 2020 Mar; 38(3):647-656. PubMed ID: 30659302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel hormonal approaches in prostate cancer.
    Friedlander TW; Ryan CJ
    Curr Oncol Rep; 2009 May; 11(3):227-34. PubMed ID: 19336015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular pathways: targeting resistance in the androgen receptor for therapeutic benefit.
    Mostaghel EA; Plymate SR; Montgomery B
    Clin Cancer Res; 2014 Feb; 20(4):791-8. PubMed ID: 24305618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New agents and strategies for the hormonal treatment of castration-resistant prostate cancer.
    Sharifi N
    Expert Opin Investig Drugs; 2010 Jul; 19(7):837-46. PubMed ID: 20524793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The androgen receptor-targeted proteolysis targeting chimera and other alternative therapeutic choices in overcoming the resistance to androgen deprivation treatment in prostate cancer.
    Li L; Xu J
    Clin Transl Oncol; 2023 Feb; 25(2):352-363. PubMed ID: 36203075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen axis in prostate cancer.
    Culig Z; Bartsch G
    J Cell Biochem; 2006 Oct; 99(2):373-81. PubMed ID: 16598769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The androgen receptor as putative therapeutic target in hormone-refractory prostate cancer.
    Kageyama Y; Hyochi N; Kihara K; Sugiyama H
    Recent Pat Anticancer Drug Discov; 2007 Nov; 2(3):203-11. PubMed ID: 18221063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Manipulation of androgens and alterations in the androgen receptor axis in prostate cancer.
    Nguyen MM; Wang Z
    Minerva Urol Nefrol; 2008 Mar; 60(1):15-29. PubMed ID: 18427432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Castration-resistant prostate cancer: locking up the molecular escape routes.
    Attar RM; Takimoto CH; Gottardis MM
    Clin Cancer Res; 2009 May; 15(10):3251-5. PubMed ID: 19447877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.